Trials / Completed
CompletedNCT05203341
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 in Adult Subjects With Major Depressive Disorder (MDD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 183 (actual)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Matching placebo tablets |
| DRUG | NBI-1065845 | NBI-1065845 tablets |
Timeline
- Start date
- 2022-02-21
- Primary completion
- 2024-01-10
- Completion
- 2024-02-21
- First posted
- 2022-01-24
- Last updated
- 2025-01-15
Locations
41 sites across 6 countries: United States, Bulgaria, Czechia, Poland, Slovakia, Sweden
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05203341. Inclusion in this directory is not an endorsement.